Additional file 5: Figure S3. of Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells

Peripheral blood counts represented as average fold change in nude (a) and C57BL/6 (b) mice 3 and 5 days after ZOL treatment, respectively (n = 4 − 5/group). c CFU assay of bone marrow, peripheral blood and spleen 3 days after CTL or ZOL treatment; n = 5 nude mice/cohort, *p < 0.05. d BrDU-positive HSCs as a percentage of total HSCs per nude mouse femur at early time points post ZOL treatment; n.s. not significant; n = 5 mice/cohort, 1 femur per mouse. (PDF 986 kb